|Home Page : www.otcjournal.com
Email Questions or Comments To: email@example.com
OTC Journal Members:
Looking back on the last six months, it seems I've had a tendency to be a little early with some of my ideas- but I'd rather be a month early than a day late.
However, I'm exaggerating. I've been a few months early- not just a couple of days. Take, for example Liberator Corp (OTC BB: LUVU)- the company I first covered back on January 8th at $.14 per share. LUVU is leading the new Sexual Revolution movement as evidenced by the large variety of sexual wellnes merchandise available in main street stores like CVS, Wallgreens, etc. Amazon.com, durgstore.com, and Vitaminshop.com are all active is this new category.
As I disclosed in my first edition on the company, I've been a shareholder for about 3 years. I helped finance the companies growth back in 2007, and still own the stock today.
I first wrote about it back then at $.14- it closed Thursday at $.35, yielding a 150% gain for investors that had the patience to own the stock for a lousy 4 months- nothing in dinosaur years, but a long time in dog years. To the most successful investors in the world, that's very short term.
As you can see from the chart, the stock blipped up back in January when I first covered it, and then got quiet for 3 months. This company has generated over $60 million in revenues since inception, and will do over $20 million this year. It's on the verge of turning profitable. Not your run-of-the-mill start up by any means.
Here's the point- a little patience can really pay off, as it has in this case. The stock is trading up and finally showing some volume. I knew it was coming, but I was a few months early. No big deal to make 150%.
Look for this one to really do well over the next couple of months. If it pulls back, pounce.
And speaking of being a little early with an idea, here's a coming
Boy, was I early on this one as well. I wrote an edition last last year when the stock was $1.25. It's since been as high as $2 (60% gain), and as low as $1.
I'm not going to spoil the fun by telling you the name and symbol of the stock. I'm just showing you the chart, so you can see what I mean. I wrote about it at $1.25, then it went comotose from January to March. Then- wow!!!!- the volume came surging in, and the stock rocketed to $2 on huge volume.
It's highly volatile and after making a 4 day run from $1.10 to $1.90, it has decided to fall back.
There have been a few developments out of the company of late, and certainly lots of volume and volatility.
This one is a trader's delight. I'll re-introduce this idea on Sunday so you can tee it up for Monday if you like it.
A reminder: Catch me live on TV every Monday from 12 to 2PM eastern.
The OTC Journal Newsletter is an electronic publication committed to providing our readers with useful information on publicly traded companies. The Newsletter contracts with publicly traded companies and receives compensation from them or third parties as payment for publishing information and opinions about the company and the trading market for their securities. Principals of the Newsletter may also purchase or sell securities of the companies in the open market from time to time. The positions, if any, that the Newsletter or its principals presently maintain in the securities of the companies are disclosed here (click here) and should be considered in making an investment decision regarding these companies securities. The Newsletter and its principals reserve the right to acquire additional shares or liquidate some or all of the positions they may hold in the issuer’s securities at any time in the future without further notice. These publications should not be considered to be independent publications concerning the company.
All statements and opinions expressed herein are those of the editors and are subject to change without notice. The Newsletter maintains editorial control over its publications and the companies profiled therein do not have any editorial rights concerning the information published about them. While we believe all sources of information provided by us and contained in our publication to be accurate and reliable, we cannot and do not guarantee the accuracy of information we received from third parties.
The information found in this profile is protected by the copyright laws of the United States and may not be copied, or reproduced in any way without the express written consent of the editors of otcjournal.com.